Jazz Pharmaceuticals plc — Director's Dealing 2020

Mar 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-03-06

Reporting Person: Larkin Finbar (SVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-06	Ordinary Shares	S	292	$119.1543	Disposed	14498	Direct
2020-03-09	Ordinary Shares	S	615	$111.489	Disposed	13883	Direct

Footnotes

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $111.4701 to $111.5101. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.